MPH:CA:CDX-Medicure Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | TSX Venture Exchange

Last Closing

USD 1.17

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

600.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medicure Inc is a biopharmaceutical company. It is engaged in the research, development and commercialization of human therapeutics. Its products include Aggrastat, Generic aNDA, Transdermal Aggrastat, and Tardoxal.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-06 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

-0.45 (-3.93%)

USD 0.13B
ZYUS:CA ZYUS Life Sciences Corporation

-0.03 (-3.66%)

USD 0.06B
LOVE:CA Cannara Biotech Inc

+0.06 (+10.00%)

USD 0.06B
SBBC:CA Simply Better Brands Corp

N/A

USD 0.05B
LSL:CA LSL Pharma Group Inc.

+0.05 (+10.00%)

USD 0.05B
PCLO:CA Pharmacielo Ltd

+0.01 (+3.70%)

USD 0.03B
DB:CA Decibel Cannabis Company Inc

N/A

USD 0.02B
ROMJ:CA Rubicon Organics Inc

+0.02 (+3.85%)

USD 0.02B
DHB:CA Delivra Health Brands Inc.

N/A

USD 7.82M
CANB:CA CanadaBis Capital Inc

+0.01 (+9.09%)

USD 7.60M

ETFs Containing MPH:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.43% 39% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.43% 39% F 45% F
Trailing 12 Months  
Capital Gain 1.74% 61% D- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.74% 61% D- 70% C-
Trailing 5 Years  
Capital Gain -76.36% 60% D- 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.36% 60% D- 21% F
Average Annual (5 Year Horizon)  
Capital Gain -6.83% 52% F 42% F
Dividend Return -6.83% 52% F 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.88% 71% C- 62% D
Risk Adjusted Return -18.51% 57% F 42% F
Market Capitalization 0.14B 57% F 61% D-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector